MK-7602 / Merck (MSD) - LARVOL DELTA

MK-7602: a potent multi-stage dual-targeting antimalarial. (PubMed, EBioMedicine) - "MK-7602 represents a new class of antimalarial for treating uncomplicated malaria with a new mechanism of action and the potential to address drug-resistant malaria. Clinical evaluation of MK-7602's activity against P. falciparum is ongoing."

Journal • Infectious Disease • Malaria

Activity of MK-7602 against blood-stage P. falciparum in a controlled human malaria infection study (ASTMH 2025) - No abstract available

Infectious Disease • Malaria

Phase 1 clinical trials of the aspartyl protease inhibitor MK-7602 in humans. (ASTMH 2025) - No abstract available

Clinical • P1 data • Infectious Disease • Malaria

148 - Aspartyl Protease Inhibitors for Plasmodium and other Apicomplexan parasites: From Screening Hits to Clinical Proof of Biology for Malaria (ASTMH 2025) - "Specifically, data will be presented for: 1) MK-7602 phase 1 Multiple Ascending dose (MAD) clinical trials, 2) MK-7602 phase 1b clinical trial using the CHIM. 3) Mode of action and inhibition of transmission by aspartic protease inhibitors in P. falciparum, 3) data showing sporozoite immunization and MK-7602 chemoprophylaxis confers immunity against malaria, 4) Activity and mode of action of aspartyl protease inhibitors in Toxoplasma and Cryptosporidium, 5) Activity and mode of action of aspartyl protease inhibitors in the Apicomplexan parasite Babesia.Content tags: #InfectiousDisease; #Therapeutics; #TranslationalScience."

Clinical • Infectious Disease • Malaria

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (clinicaltrials.gov) - P1 | N=34 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | N=16 ➔ 34

Enrollment change

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Jul 2025 | Trial primary completion date: Apr 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Completed | N=42 ➔ 16

Enrollment change • Trial completion • Infectious Disease • Malaria

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria